NEW YORK (360Dx) – Sysmex America recently said that it is entering the routine clinical flow cytometry market by offering a portfolio of analyte-specific reagent antibodies.

The move is a logical progression for the firm in a market that needs a third large industry player to join Becton Dickinson and Beckman Coulter, Joshua Johnson, corporate and key account executive of flow cytometry at Sysmex America, said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.